Mustang Bio, Inc, a clinical-stage biopharmaceutical company, focuses on translating medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline focuses on gene therapy programs for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone781-652-4500
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees38
Next Earnings Date11/12/2019 (Estimated)
OptionableOptionable
Mustang Bio (NASDAQ:MBIO) Frequently Asked Questions
What is Mustang Bio's stock symbol?
Mustang Bio trades on the NASDAQ under the ticker symbol "MBIO."
How were Mustang Bio's earnings last quarter?
Mustang Bio Inc (NASDAQ:MBIO) issued its earnings results on Friday, August, 9th. The company reported ($0.29) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.24) by $0.05. View Mustang Bio's Earnings History.
When is Mustang Bio's next earnings date?
What price target have analysts set for MBIO?
3 brokerages have issued 12 month price objectives for Mustang Bio's shares. Their forecasts range from $7.00 to $18.00. On average, they expect Mustang Bio's share price to reach $10.6667 in the next year. This suggests a possible upside of 164.0% from the stock's current price. View Analyst Price Targets for Mustang Bio.
What is the consensus analysts' recommendation for Mustang Bio?
3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Mustang Bio in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Mustang Bio.
Has Mustang Bio been receiving favorable news coverage?
News stories about MBIO stock have been trending somewhat negative recently, according to InfoTrie. The research group scores the sentiment of press coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Mustang Bio earned a news impact score of -1.3 on InfoTrie's scale. They also assigned media headlines about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the company's share price in the next few days. View News Stories for Mustang Bio.
Are investors shorting Mustang Bio?
Mustang Bio saw a increase in short interest in August. As of August 31st, there was short interest totalling 1,201,600 shares, an increase of 18.5% from the July 31st total of 1,013,700 shares. Based on an average daily volume of 288,900 shares, the days-to-cover ratio is currently 4.2 days. Approximately 4.3% of the shares of the company are short sold. View Mustang Bio's Current Options Chain.
Who are some of Mustang Bio's key competitors?
Some companies that are related to Mustang Bio include Catalyst Pharmaceuticals (CPRX), Advanz Pharma (CXRXF), Vectura Group (VEGPF), ZEALAND PHARMA/S (ZEAL), OrganiGram (OGI), MacroGenics (MGNX), Revance Therapeutics (RVNC), Synthorx (THOR), TG Therapeutics (TGTX), DiaMedica Therapeutics (DMCAF), Flexion Therapeutics (FLXN), Aurinia Pharmaceuticals (AUPH), Organogenesis (ORGO), Lannett (LCI) and Myovant Sciences (MYOV).
What other stocks do shareholders of Mustang Bio own?
Who are Mustang Bio's key executives?
Mustang Bio's management team includes the folowing people:
- Mr. Michael S. Weiss, Exec. Chairman (Age 53)
- Dr. Manuel Litchman, Pres, CEO & Director (Age 65)
- Mr. David Jay Horin CPA, Interim Chief Financial Officer (Age 51)
- Mr. Brian K. Achenbach, VP of Fin. & Corp. Controller (Age 54)
- Dr. Knut Niss, Chief Technology Officer
Who are Mustang Bio's major shareholders?
Mustang Bio's stock is owned by many different of institutional and retail investors. Top institutional investors include BlackRock Inc. (4.31%), Vanguard Group Inc. (4.04%), Renaissance Technologies LLC (1.34%), Northern Trust Corp (0.57%), FNY Investment Advisers LLC (0.50%) and National Asset Management Inc. (0.27%). View Institutional Ownership Trends for Mustang Bio.
Which institutional investors are selling Mustang Bio stock?
Which institutional investors are buying Mustang Bio stock?
MBIO stock was bought by a variety of institutional investors in the last quarter, including Vanguard Group Inc., BlackRock Inc., Renaissance Technologies LLC, FNY Investment Advisers LLC, Acadian Asset Management LLC, Northern Trust Corp, Bank of New York Mellon Corp and Quinn Opportunity Partners LLC. View Insider Buying and Selling for Mustang Bio.
How do I buy shares of Mustang Bio?
Shares of MBIO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Mustang Bio's stock price today?
One share of MBIO stock can currently be purchased for approximately $4.04.
How big of a company is Mustang Bio?
Mustang Bio has a market capitalization of $163.42 million. The company earns $-30,660,000.00 in net income (profit) each year or ($1.14) on an earnings per share basis. Mustang Bio employs 38 workers across the globe.View Additional Information About Mustang Bio.
What is Mustang Bio's official website?
How can I contact Mustang Bio?
Mustang Bio's mailing address is 2 GANSEVOORT STREET 9TH FLOOR, NEW YORK NY, 10014. The company can be reached via phone at 781-652-4500 or via email at [email protected]
MarketBeat Community Rating for Mustang Bio (NASDAQ MBIO)
MarketBeat's community ratings are surveys of what our community members think about Mustang Bio and other stocks. Vote "Outperform" if you believe MBIO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MBIO will underperform the S&P 500 over the long term. You may vote once every thirty days.
